Y. Lu

A comparison of the effects of raloxifene and estrogen on bone in postmenopausal women.

Yili Lu, D. Muchmore, L. Raisz, 2000, The Journal of clinical endocrinology and metabolism.

Efficacy and safety of metformin and sodium-glucose co-transporter-2 inhibitors in adults with type 1 diabetes: A systematic review and network meta-analysis

Q. Zhang, Y. Lu, X. Fei, 2020 .

NVA237 Once Daily Provides Rapid And Sustained Bronchodilation In COPD Patients, With Efficacy Similar To Tiotropium: The GLOW2 Trial

E. Kerwin, J. Hébert, D. Banerji, 2012, ATS 2012.

Efficacy of statin pretreatment for the prevention of contrast‐induced nephropathy: a meta‐analysis of randomised controlled trials

J. Ge, H. Jiang, L. Zhang, 2011, International journal of clinical practice.

NVA237 once daily reduces the percentage of patients with exacerbations of COPD and associated hospitalizations: The GLOW1 trial

G. Ferguson, A. D’Urzo, D. Banerji, 2011 .

Characterization of hot flashes reported by healthy postmenopausal women receiving raloxifene or placebo during osteoporosis prevention trials.

F. Cohen, Yili Lu, Y. Lu, 2000, Maturitas.

Adverse events reported by postmenopausal women in controlled trials with raloxifene.

L. Plouffe, Yili Lu, W. Huster, 1999, Obstetrics and gynecology.

Effect of raloxifene on breast cancer cell Ki67 and apoptosis: a double-blind, placebo-controlled, randomized clinical trial in postmenopausal patients.

M. Dowsett, F. Cohen, P. Veronesi, 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

Effects of Raloxifene on Fracture Severity in Postmenopausal Women with Osteoporosis: Results from the MORE Study

H. Genant, Ying Lu, T. Fuerst, 2002, Osteoporosis International.

P-85. Characterization of Hot Flashes During Raloxifene Therapy: Analyses of Adverse Event Reports from an Integrated Placebo-Controlled Clinical Trial Database

M. Lakshmanan, Y. Lu, F. Cohen, 1998 .

P252 Once-daily NVA237 improves symptoms, and reduces COPD exacerbations and associated hospitalisations: the GLOW1 trial

V. Alagappan, D. Banerji, T. Overend, 2011, Thorax.

P253 NVA237 once daily offers rapid and clinically meaningful bronchodilation in COPD patients that is maintained for 24 h: the GLOW1 trial

V. Alagappan, D. Banerji, T. Overend, 2011, Thorax.